At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options. With collaborations with Sarah Cannon Research Institute (SCRI) and VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.
BREAST CANCER - NEOADJUVANT
24301: A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer. Click here to learn more
BREAST CANCER - ADJUVANT
A012301: A randomized, phase 3 clinical trial of low‐dose tamoxifen for selected patients with molecular low-risk early‐stage breast cancer. Click here to learn more
BREAST CANCER - METASTATIC
24325: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) vs Treatment of Physician's Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment. Click here to learn more
25007: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer. Click here to learn more
COLORECTAL
25216: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer. Click here to learn more
HEAD & NECK
USOR 24-004: A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma. Click here to learn more
LUNG
24188: A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer. Click here to learn more
24305: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations. Click here to learn more
25091: A randomized, phase 3, open-lable study to evaluate PF-08046054/SGN-PDL1V vs docetaxel in adult participants with previously-treated PD-L1 positive Non-Small Cell Lung Cancer (NSCLC). Click here to learn more
25153: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 > 50%. Click here to learn more
PREVENTION
URCC 22063: Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia. Click here to learn more
WF-2304-172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics. Click here to learn more